Immersive Virtual Reality and Exercise Programs in Multiple Sclerosis: ExeRVIEM III (ExeRVIEM III)
Effects of a Physiotherapy Program With High-Intensity Exercise and Immersive Virtual Reality in Multiple Sclerosis: Randomized Controlled Trial
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Pablo Campo-Prieto, PhD
- Telefonnummer: 986801770
- E-mail: pcampo@uvigo.gal
Studiesteder
-
-
-
Pontevedra, Spanien
- Rekruttering
- University of Vigo
-
Kontakt:
- Dr. Pablo Campo Prieto, PhD
- Telefonnummer: +034 986801750
- E-mail: pcampo@uvigo.gal
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- ≥18 years of age.
- Confirmed diagnosis of MS.
- Stable disease with no relapse in the previous 6 weeks.
- Patients who will be take follow up by a neurologist at the referral hospital and will be members of the patient association.
- Ability to perform moderate exercise.
- Capacity to provide informed consent.
Exclusion Criteria:
- Comorbidities that hinder the development of the VR program
- Visual or vestibular impairment that would contraindicate VR use.
- Recent changes in disease modifying therapy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ExeRVIEM III Protocol + Standard rehabilitation
Virtual exercise based program + Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
|
The intervention will consist of a supervised virtual rehabilitation program delivered over 6 months, with two sessions per week on alternating days.
An Immersive Virtual Reality body combat-based exergame executed through a VR headset will be used.
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).
|
|
Aktiv komparator: Standard rehabilitation
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognition sessions)
|
Standard rehabilitation provided by the clinical team of the patient association (physiotherapy, occupational therapy and cognitive training sessions).
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Level of disability using the Expanded Disability Status Scale (EDSS)
Tidsramme: Baseline
|
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death).
Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability.
|
Baseline
|
|
Level of disability using the Expanded Disability Status Scale (EDSS)
Tidsramme: week 24
|
EDSS quantifies Multiple sclerosis (MS) related disability on a scale from 0 (normal neurological exa-mination) to 10 (MS related death).
Lower scores indicate less disability and generally, and a change of between 0.5 and 1.0 points on the EDSS scale is considered clinically significant, indicating actual progression or improvement in disability
|
week 24
|
|
Gait evaluated by 25Foot Walk Test (25FWT)
Tidsramme: Baseline
|
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity.
The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
|
Baseline
|
|
Gait evaluated by 25Foot Walk Test (25FWT)
Tidsramme: Week 24
|
25FWT assesses walking speed over 25 feet; shorter times reflect better gait capacity.
The 25FWT is a validated, reliable measure accepted by regulatory consortia, predictive of disability progression, where a change greater than 20% in the time taken to walk 25 feet (7.6 meters) is considered relevant to the patient's daily life, indicating a real improvement or deterioration of their functional capacity, beyond the natural variability of the test.
|
Week 24
|
|
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Tidsramme: Baseline
|
9HPT (right and left) evaluates fine manual dexterity.
Lower times indicate better performance.
Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes.
Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
|
Baseline
|
|
Manual dexterity assessed by 9-Hole Peg Test (9HPT)
Tidsramme: Week 24
|
9HPT (right and left) evaluates fine manual dexterity.
Lower times indicate better performance.
Reductions of approximately 20% are often considered clinically meaningful, particularly in progressive Multiple sclerosis (MS) phenotypes.
Often in clinical studies, a change of 2 seconds or more in the average test execution time is considered clinically relevant, indicating an impairment in manual dexterity and fine motor function
|
Week 24
|
|
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Tidsramme: Baseline
|
SDMT assesses cognitive processing speed; higher scores indicate better performance.
The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
|
Baseline
|
|
Cognitive domains evaluated by the Symbol Digit Modalities Test (SDMT)
Tidsramme: Week 24
|
SDMT assesses cognitive processing speed; higher scores indicate better performance.
The SDMT is highly sensitive to cognitive impairment in Multiple sclerosis (MS) and a variation of 4 to 5 points (or a change of at least 10% from baseline) is generally considered to indicate a real and clinically relevant change in the patient's cognitive performance
|
Week 24
|
|
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Tidsramme: Baseline
|
sNfL expressed in serum (pg/mL) evaluates disease progression.
Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity.
In this study, it was performed using an automated assay for measuring sNfL.
|
Baseline
|
|
Axonal injury biomarker evaluated by Neurofilament light chain (sNfL) concentrations
Tidsramme: Week 24
|
sNfL expressed in serum (pg/mL) evaluates disease progression.
Lower levels suggest reduced neuroaxonal damage and may reflect decreased disease activity.
In this study, it was performed using an automated assay for measuring sNfL.
|
Week 24
|
|
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Tidsramme: Baseline
|
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movement (5 repetitions standing up and sitting in a chair).
Lower times indicate better performance.
|
Baseline
|
|
Lower limbs strength evaluated by five times sit to stand test (FTSST)
Tidsramme: Week 24
|
FTSST is used to objectively determine measures to provide a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements (5 repetitions standing up and sitting in a chair).
Lower times indicate better performance
|
Week 24
|
|
Functional mobility evaluated by five timed and go test (TUG)
Tidsramme: Baseline
|
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance.
The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.
Lower times indicate better performance.
|
Baseline
|
|
Functional mobility evaluated by five timed and go test (TUG)
Tidsramme: Week 24
|
TUG is a standardized test to assess the basic functional mobility of elderly persons and requires both static and dynamic balance.
The patient is observed and timed while he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again.
Lower times indicate better performance.
|
Week 24
|
|
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Tidsramme: Baseline
|
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three).
It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment.
Lower times indicate better performance.
|
Baseline
|
|
Dual task performance evaluated by five timed and go test- cognitive (TUG-cog)
Tidsramme: Week 24
|
It involves performing the TUG physical test while simultaneously carrying out a mental task (such as counting backwards in increments of three).
It is an ideal tool for assessing the ability to multitask in older adults or individuals with neurological impairment.
Lower times better performance.
|
Week 24
|
|
Upper limbs strength evaluated by handgrip test
Tidsramme: Baseline
|
A handgrip strength test measures the maximum force your hand and forearm muscles can make.
It acts as a key indicator for overall body strength and healthy aging.
Higher scores indicates better performance.
|
Baseline
|
|
Upper limbs strength evaluated by handgrip test
Tidsramme: Week 24
|
A handgrip strength test measures the maximum force your hand and forearm muscles can make.
It acts as a key indicator for overall body strength and healthy aging.
Higher scores indicates better performance.
|
Week 24
|
|
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Tidsramme: Baseline
|
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis.
Lower scores in the scale indicate less fatigue.
|
Baseline
|
|
Levels of fatigue evaluated with The Fatigue Severity Scale (FSS)
Tidsramme: Week 24
|
The FSS is a questionnaire with 9 questions that measures the extreme fatigue that affects many people with multiple sclerosis.
Lower scores in the scale indicate less fatigue.
|
Week 24
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Pablo Campo-Prieto, PhD, University of Vigo
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HEALTHYFIT-UVIGO 3/2026
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .